Updated:
Transcarent
The business was co-founded in 2020 by Glen Tullman, the former Allscripts and Livongo CEO, who recruited early backing from General Catalyst and...
Transcarent
The business was co-founded in 2020 by Glen Tullman, the former Allscripts and Livongo CEO, who recruited early backing from General Catalyst and 7wireVentures. Tullman positioned Transcarent as a direct-contracting alternative to traditional insurance carriers shortly after Livongo's $18.5B sale to Teladoc — an exit that gave the team an operating playbook for scaling a condition-specific digital-health platform inside self-insured workforces. Transcarent contracts with large employers on a per-employee-per-month model tied to total cost of care reductions. The platform spans four integrated care experiences — WayFinding (benefits navigation and clinical triage), Pharmacy Care, Weight Health, and Surgery Care — supplemented by Cancer Care and the firm's acquired 2nd.MD expert-opinion service. WayFinding encodes a generative-AI concierge that ingests a member's plan design and past interactions to route them to a nurse guide, a virtual primary-care visit, or a scheduled video consultation. Competitors include Accolade, Included Health, and legacy carrier-navigation apps, but Transcarent's risk-based pricing architecture differentiates it from purely SaaS point solutions. The firm maintains joint headquarters in Chicago and Denver and has disclosed no public AUM. The company has played into the employer stop-loss and referral-management stack, not the provider or payer balance sheet — its capital commitments serve as operating runway rather than a balance-sheet investment vehicle. Adjacent affiliations include 7wireVentures, Tullman's venture firm, though Transcarent itself has not announced a philanthropic foundation or an open co-investor club. Transcarent's single structural bet is that a payer-agnostic layer — owned by the employer, not the carrier — can reroute tens of billions in annual US claims spending into lower-cost, higher-accountability care pathways without disrupting existing plan relationships. Tullman embedded national Centers of Excellence contracts (surgery bundled payments) and a mail-order specialty pharmacy inside the same per-member subscription, making Transcarent an operating company that gets paid only when utilization data proves it saved the plan money.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Chicago, Denver
Corporate office
Chicago, Denver, United States
Sector focus
Frequently asked questions
Who runs investment decisions at Transcarent?
Transcarent is an operating company, not an investment firm. Strategic decisions rest with co-founder and CEO Glen Tullman. The board includes representatives from major venture backers such as General Catalyst, though the company discloses neither a chief investment officer nor a family-office investment committee.
How does Transcarent source its business?
Transcarent sells directly to large self-insured employers — Pilot Company, for example, has publicly endorsed the platform. Deals originate through the founder's network, benefits-consultant channels, and direct enterprise sales; the company does not operate a GP-LP fundraising model. It competes for employer budget that would otherwise fund fragmented point solutions or a traditional carrier's navigation module.
Is Transcarent structured as a single family office or does it operate more like a venture firm?
Transcarent is a venture-backed operating company that generates revenue by managing employer health spend, not by managing asset portfolios. It has raised disclosed rounds from institutional firms including General Catalyst and 7wireVentures but does not function as a family office, a fund, or a pooled investment vehicle. The Altss database classifies it as an operating asset-manager analog because it bears financial risk on patient outcomes.
What is Transcarent's known posture on co-investments alongside external GPs?
Transcarent has not announced a co-investment program. Its capital structure relies on venture equity and operating revenue, and there is no public record of the company syndicating opportunities to external limited partners or family-office investors. Any future round would likely follow the existing venture-backed path rather than opening a club-deal platform.
Which sectors does Transcarent explicitly avoid?
Transcarent's platform is built exclusively for employer-sponsored health benefits, which means it does not sell into Medicare Advantage, Medicaid managed-care organizations, or direct-to-consumer channels. It also avoids building a provider-facing electronic health record, staying on the care-navigation and bundled-contracting layer instead of entering the clinical documentation or revenue-cycle markets.
Where does the underlying wealth come from?
No single-family wealth anchors Transcarent. The company was formed with institutional venture capital, most notably from General Catalyst and Tullman's own 7wireVentures, which itself was capitalized with returns from prior healthcare exits rather than from inherited family assets. There is no publicly disclosed single-family entity behind the firm.
Does Transcarent maintain philanthropic structures, and how are they separated?
Transcarent has not established a corporate foundation or donor-advised fund structure that publicly reports grants. Glen Tullman's personal and venture-entity giving is separate from the company's operating balance sheet, but no formal philanthropic vehicle bearing the Transcarent name has been disclosed.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: